Press Releases

Press Releases

    Date Title View
    10/17/19
    Summary ToggleFORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
    PDF Version
    10/17/19
    Summary ToggleHorizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
    PDF Version
    10/11/19
    Summary ToggleNew Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
    PDF Version
    10/10/19
    Summary ToggleFor World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
    PDF Version
    10/09/19
    Summary ToggleHorizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
    PDF Version
    10/08/19
    Summary ToggleNew Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
    PDF Version
    10/03/19
    Summary ToggleHorizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
    PDF Version
    09/09/19
    Summary ToggleHorizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
    PDF Version
    08/28/19
    Summary ToggleHorizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
    PDF Version
    08/19/19
    Summary ToggleAmerican Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)
    PDF Version
    Displaying 11 - 20 of 472 results